Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The Indian pharmaceuticals industry is expected to log in a revenue growth of 8-10 per cent in current fiscal aided by a steady domestic growth and increased exports to regulated markets, even as semi-regulated markets face headwinds, according to a report. A study of 186 drug makers, which accounted for about half of the Rs 3.7 lakh crore annual revenue of the sector last fiscal, indicates as much, <keyword id="6359483" type="General" weightage="100" keywordseo="crisil" source="Orion">Crisil</keyword> said on Monday. "Similar to last fiscal, domestic growth in fiscal 2024, will be led by 5-6 per cent increase in realisations, supported partly by high price hikes allowed by the <keyword id="390804" type="General" weightage="50" keywordseo="national-pharmaceutical-pricing-authority" source="Orion">National Pharmaceutical Pricing Authority</keyword> (NPPA) for drugs under price regulation," Crisil Research Director <keyword id="13891160" type="General" weightage="50" keywordseo="aniket-dani" source="Orion">Aniket Dani</keyword> said. In addition, sale of existing drugs and new launches will drive 3-4 per cent volume growth, he added. Operating profitability is also seen improving 50-100 basis points (bps) to 21 per cent this fiscal, supported by moderation in input and logistics costs, and abating pricing pressure in the US generics market, it said. This follows two consecutive years of margin contraction due to high pricing pressure in the US and a sharp rise in input costs caused by supply chain disruption during the Covid pandemic, and thereafter, Crisil noted. Credit profiles will remain stable owing to low-leverage balance sheets and moderate capex plans, it stated. In the ongoing fiscal, domestic sales are expected to witness 8-10 per cent growth with the chronic segment expected to be the key contributor to revenues, because of the steady increase in lifestyle-related diseases and continued emphasis on health awareness, post the pandemic, Crisil said. Formulation exports are seen up 7-9 per cent in rupee terms this fiscal, more driven by volumes, from new product launches, and abating price pressure in the US generics markets, it said. On the other hand, increase in claw-back taxes in select <keyword id="28249" type="General" weightage="50" keywordseo="europe" source="Orion">Europe</keyword>an markets could lead to lower growth in exports to Europe this fiscal, it added. "Growth in exports to Asia will improve this fiscal, after clocking a modest growth last fiscal, while exports to Africa will continue to remain sluggish on account of low forex reserves (impacting the purchasing power) and high currency volatility," Crisil said. Lower input prices and normalisation of supply chains should cull inventories to pre-pandemic levels, resulting in smaller incremental working capital debt this fiscal, it added. SEE ALSO:<a href="https://www.businessinsider.in/tech/news/pixel-watch-2-gets-set-to-take-on-galaxy-watch-6-and-apple-watch-series-9-in-india/articleshow/103567404.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/pixel-watch-2-gets-set-to-take-on-galaxy-watch-6-and-apple-watch-series-9-in-india/articleshow/103567404.cms" target="_blank">Pixel Watch 2 gets set to take on Galaxy Watch 6 and Apple Watch Series 9 in India</a> <a href="https://www.businessinsider.in/tech/mobile/news/how-the-iphone-15-and-iphone-15-pro-models-will-differ/articleshow/103513314.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/news/how-the-iphone-15-and-iphone-15-pro-models-will-differ/articleshow/103513314.cms" target="_blank">Here’s how the iPhone 15 and iPhone 15 Pro models will differ</a> <a href="https://www.businessinsider.in/business/auto/news/volvo-c40-recharge-with-530-km-range-launched-in-india-for-61-25-lakh/articleshow/103382328.cms">Volvo C40 Recharge with 530 km range launched in India for ₹61.25 lakh</a>

Indian pharma industry to log in 8-10% revenue growth this fiscal: Crisil

New Delhi, Jan 28 () The growth trajectory for the Indian pharmaceutical industry is likely to remain at 10-13 per cent in 2020-21 despite challenges, according to rating agency Icra.
The expected growth in the next financial year is on the back of healthy demand from the domestic market given increasing spend on healthcare along with improving access, Icra said in a statement.
This along with abatement in pricing pressure for the US market, new launches and market share gains for existing products and consolidation benefits will drive growth in 2020-21, it added. 
"The Indian pharmaceutical industry's growth remained stable at 12.2 per cent during H1 FY2020 led by rebound in domestic growth in Q2 FY2020 to 14.2 per cent supported by seasonal factors and stable growth in chronic therapies," Icra Vice President &amp; Co-Head Gaurav Jain said.
 During Q2 FY2020, India witnessed outbreak of many diseases in many parts, aiding the growth of the anti-infective segment, he added.
Though margins remain healthy, pricing pressures for the US base generics business (albeit moderating), lack of limited competition products and manufacturing quality issues will continue to put margin pressure, Icra said.
Higher share of domestic business and operational efficiencies will provide overall cushion to margins, it added.
The key sensitivities to growth and profitability estimated of the Indian pharma industry will be regulatory interventions such as price controls and compulsory genericisation for domestic market and continued regulatory overhang with respect to manufacturing quality deficiencies during USFDA audits, the statement said.
"The US market growth at 13.6 per cent in H1 FY2020 was impacted by regulatory overhang in the form of warning letters, one-offs such as delayed shipments, voluntary recall, though few limited competition products, lower pricing pressure, volume expansion for existing and new product launches supported growth," Jain said.
Unlike in the past, when several Indian pharma companies ramped up their R&amp;D spend targeting pipeline of specialty drugs, niche molecules and complex therapies, this time around companies are optimising their R&amp;D spend, the statement said.
"The credit metrics of leading pharma companies are expected to remain stable in view of future growth prospects in regulated markets and relatively strong balance sheets," Jain said.
The capital structure and coverage indicators are expected to remain strong despite pressure on profitability and marginal rise in debt levels given inorganic investments, he added.
"The key sensitivity to ICRA's view remains productivity of R&amp;D expenditure, increasing competition in the US generics space and operational risk related to increased level of due diligence by regulatory agencies," Jain said. AKT AKT ANU
ANU

Indian pharma industry likely to grow at 10-13 pc in FY'21: Icra

New Delhi, May 13 () The Indian pharma industry on Wednesday hailed Prime Minister Narendra Modi emphasising on making India self-reliant and said his speech captured the need of the moment in these trying times. "The Prime Minister's speech captured the need of the hour perfectly. IPA lauds PM's vision on 'Vasudhaiva Kutumbakam' and self-reliance," Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain said in a statement.During these unprecedented times, the pharmaceutical industry has worked with the government in an integrated manner and continued to operate with vigour to drive local expertise and truly live up to its title as the 'Pharmacy of the World', he added."Having said that, providing impetus to domestic manufacturers will strengthen the industry going forward. This will usher a new era for the country's healthcare and pharma sector," Jain said. The government had earlier come out with greater contours of active pharmaceutical ingredient (API) policy which is expected to increase self-reliance in fermentation-based API industry, he added."IPA is committed to providing quality medicines to the patients in need and we applaud Hon'ble PM's vision for a self-reliant India," Jain said.In similar vein, the Indian Drug Manufacturers' Association (IDMA) also praised Modi's speech on emphasis on self-reliance."The PM has very rightly mentioned in his address to nation that it was only the 'local' which came to our help during these unprecedented times," IDMA Executive Director Ashok Kumar Madan said.Whether HCQ or any other formulation, India's uninhibited exports to all nations and its neighbours have again proved India's image as 'Pharmacy of the World', he added. "IDMA with its membership of large, medium and small enterprises across the country, reassures the nation of pharma industries' commitment to serve the nation and the humanity," Madan said. AKT MKJ

Modi's 'self-reliance' call need of the hour: Pharma industry

A joint report by PeopleStrong, Wheetbox, CII and LinkedIn revealed that the pharma and health sector will see an increase in hiring by 20% as compared to 7.2% in 2015. 
 The India Skills Report 2016 stated that the pharma and <keyword id="54598" type="UNKNOWN" weightage="20" keywordseo="Healthcare-sector">healthcare sector</keyword>, which presently employs around 5.5 lakh people, will create 1, 34, 000 jobs in 2016. 
 
The report also placed the Indian pharma industry in top 10 global markets in value terms by 2020. 
 
So what will be the key skills that the pharma sector will be looking for this year? 
 
The employers will prefer hiring freshers (33.6%). People with five years of work experience having skilled domain expertise in the age group of 22-25 years will see an up in hiring by 32%. 
 The need of skilled manpower in the <keyword id="189164" type="UNKNOWN" weightage="20" keywordseo="pharmaceutical-industry">pharmaceutical industry</keyword> ranges widely from R&amp;D, Quality Assurance (QA), Intellectual Property (IP), manufacturing to even sales and marketing. 
 
The sector still prefers to look for candidates through job portals (25%) &amp; HR consultants (18.75%). 
 
Also, the maximum hiring in this sector will be seen from Karnataka, Kerala and Tamil Nadu. 
 
(Image: Thinkstock)

Hiring in pharma sector will go up 20% in 2016. Here are the skills you will require

<ul><li>Business Insider reached out to several experts to understand the impact of Trump’s new proposal to import <keyword id="971519" type="PERSON" weightage="20" keywordseo="cheaper-drugs">cheaper drugs</keyword> from other countries. </li><li>Some experts see this order providing good news for the Indian pharmaceutical companies; adding that it could help increase their global presence. </li><li>On the other hand, some experts believe that Trump’s plan to cut prescription drug prices could negatively impact <keyword id="1413836" type="PERSON" weightage="20" keywordseo="Indian-pharmaceutical-companies">Indian pharmaceutical companies</keyword> and may limit the opportunities ahead. </li></ul>US President Donald Trump, on July 25, proposed four orders that would allow the American government Singhto import cheaper drugs from abroad and provide it to American citizens at a lower price. While the move benefits American citizens, it also has a direct impact on the pharmaceutical industries of countries like Canada, China, and India. Previously, in 2018, Indian firms accounted for 35-40% of the global USFDA 971 approval, <a href="https://www.gbreports.com/article/the-worlds-pharmacy-indias-generic-drug-industry">according to Global Business Reports. </a> So what does this move mean for Indian pharmaceutical companies? Business Insider reached out to several experts to understand the impact of Trump’s new proposal to import cheaper drugs from other countries. Impact on Indian pharma companies According to Shailesh Shah, Senior Partner, and founder at Strta Consulting, the proposed order can be a piece of good news for the Indian pharmaceutical companies. “If the orders do pass, it will be a boom time for countries that are exporting lower cost patent expired copies to America. Irrespective of circumstances, their repurposed uses would increase. Their sales would go up.” Shah told Business Insider India. The proposed orders are also likely to increase the presence of Indian pharmaceutical industry globally, believes Dr. Shuchin Bajaj, Founder Director, <keyword id="9661943" type="COMPANY" weightage="20" keywordseo="ujala-cygnus-healthcare-services">Ujala Cygnus Healthcare Services</keyword>. Should Indian pharma companies be worried? On the other hand, some experts believe these orders might have a negative impact and may limit the opportunities for Indian pharmaceutical companies. “The impact of Donald Trump’s executive orders on Indian drug companies will be either neutral or negative. While the order related to the passing through of the rebates to patients will primarily impact the middlemen, the order which states that the US drug prices should be based on international pricing could negatively impact companies that sell speciality drugs and biosimilars,”Mahesh Singhi, Managing Director and Founder of Singhi Advisors told Business Insider India. Mr. Arvind Sharma, Partner, Shardul Amarchand Mangaldas &amp; Co believes these orders, if passed, might hamper the series of measures taken by the Indian government to strengthen the pharmaceutical sector. “It may be noted that the government has taken a series of measures to strengthen the pharma sector, including introducing the concept of pharma parks where investments will be made in common infrastructure and providing production incentives. Such measures have been introduced with a view to make the Indian pharma sector self-sufficient and encash on the global opportunity for this sector. The aforesaid orders make the situation complex and limit the opportunity for the pharma sector”. It is still too soon to determine the impact of the proposal “We need to wait for more specifics on the drugs covered etc but it's probably unlikely to impact the Indian pharma exporters much, since there has already been significant price erosion in the last three years,” Ms. Charu Sehgal, Partner and Leader, Life Sciences and Healthcare, <keyword id="6356108" type="COMPANY" weightage="20" keywordseo="deloitte-india">Deloitte India</keyword> Moreover, this news comes at a time when Donald Trump is facing re-election in the next few months, and this makes the execution of these orders a bit challenging. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/mahindra-and-mahindra-finance-managing-director-gets-candid-about-the-rights-issue/articleshow/77212386.cms">EXCLUSIVE: M&amp;M Financial Managing Director gets candid about the rights issue, the bleak prospects for this year and why there should be no more loan moratorium</a> <a href="https://www.businessinsider.in/stock-market/news/india-stock-brokers-hit-by-sebi-direct-market-access/articleshow/77198064.cms">India's broking industry just got the shock of its life – SEBI may soon allow investors to trade directly on the exchanges</a> <a href="https://www.businessinsider.in/business/startups/news/these-10-indian-colleges-have-produced-indias-most-funded-startup-owners/slidelist/77140792.cms">These 10 Indian colleges have produced India’s most funded startup owners</a>

Boon or a bane: What does Trump’s latest proposal to import cheaper drugs mean for Indian pharma companies?

<ul><li>The shares of <keyword id="6444828" type="ORGANIZATION" weightage="20" keywordseo="gland-pharma">Gland Pharma</keyword> listed at a premium of 12% over the issue price band.</li><li>In minutes after its debut, the shares gained over 6% and were trading at ₹1795.30 a piece at 10:04 am.</li><li>Gland Pharma's total market cap rose to ₹28,636.54 crore. </li></ul>The ₹6,480 crore initial public offering of the Chinese promoter Fosun Pharma-backed Gland Pharma made a lot of money for its IPO investors despite a subdued response during the public issue. Top brokerages had advised caution on Gland Pharma, given its China connection. However, investors could not resist its strong financial performance and the fear of missing out has helped the company record a stellar debut on Dalal Street. The shares listed at a premium of 12% over the issue price band. And, in minutes after listing debut the shares gained over 6% and were trading at ₹1795.30 a piece at 10:04 am in a firm market. This is the 13th company to list this year and the largest ever public issue in the Indian pharma industry. Gland Pharma total market cap rose to ₹28,636.54 crore at 10:03 am. A total traded quantity of 1.39 lakh shares changed hands on BSE amounting to a turnover of ₹23.86 crore. The company will trade with the symbol of ‘GLAND’ on the Indian stock exchanges. <div type="image" title="Gland Pharma share" msid="79316011" hostid="261"></div> Rising demand for Gland Pharma So far this year, nearly every company that recorded a tepid response during their IPO saw a discounted listing. And, the IPO’s of UTI AMC, Likhitha Infrastructure and Angel Broking are proof of that. However, the shares of Gland Pharma were piping hot in the grey market ahead of its listing, and the market premium suggested an upside of <a href="https://www.businessinsider.in/stock-market/news/gland-pharma-shares-demand-is-rising-in-the-grey-market-ahead-of-its-listing-tomorrow/articleshow/79302810.cms">7% a day before listing</a>. Given that the Chinese promoter backs it, <a href="https://www.businessinsider.in/stock-market/news/heres-all-you-need-to-know-about-indias-largest-pharmaceutical-ipo-gland-pharma/articleshow/79125211.cms">top brokerages had advised caution</a>, despite its strong financial background, growing industry and diversified portfolio. Choice research report for its IPO highlighted that anti-Chinese sentiment after the recent geopolitical tension in the Galwan valley may disrupt its business. What worked for Gland Pharma? Strong balance sheet Gland Pharma has a successful track record of operating a B2B model with leading pharmaceutical companies such as Sagent Pharmaceuticals and Apotex as well as Fresenius Kabi USA and Athenex Pharmaceutical Division in the United States and the Rest of the world. <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Manufacturing facilities </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">2 sterile injectables facilities </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1 Penems facility </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">1 oncology facility </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">3 API facilities </td></tr></tbody></table> <div type="image" title="Gland Pharma profit and revenue (2)" msid="79317475" hostid="261"></div> Diversified business — spread over 60 countries With its business spread over 60 countries, the company has a great track record of revenue delivery and profitability across the United States, Europe, Canada, Australia, India and the rest of the world, according to Axis Securities. <div type="image" title="Gland Pharma Revenue break up" msid="79317490" hostid="261"></div> As of June 30, the company earns nearly 63% of its revenue from the US and nearly 15% from India — these two countries are the biggest market for Gland Pharma.The expansion in various other countries helps in offsetting the slowdown impact in a particular region or a country. SEE ALSO: <a href="https://www.businessinsider.in/tech/apps/news/pubg-mobile-india-was-supposed-to-launch-today/articleshow/79315462.cms" data-type="tilCustomLink">PUBG Mobile India was rumoured to launch today — but there is no official update from the company</a> <a href="https://www.businessinsider.in/stock-market/news/vodafone-idea-shares-jump-after-selling-stake-in-indus-towers-for-3760-crore/articleshow/79316662.cms" data-type="tilCustomLink">Vodafone Idea soars nearly 5% on fund infusion from Indus Towers stake sale</a>

FOMO helps Gland Pharma swell on debut

<ul><li>Actor <keyword id="6354625" type="General" weightage="80" keywordseo="vijay-sethupathi" source="Orion">Vijay Sethupathi</keyword> has been roped in as the brand ambassador of Mankid Pharma.</li><li>As a part of the association, <keyword id="146847" type="General" weightage="80" keywordseo="mankind-pharma" source="Orion">Mankind Pharma</keyword> will donate Rs 31 lakh to the Film Employees Federation of South India (FEFSI).</li></ul>Pharmaceutical company <keyword id="111790" type="General" weightage="100" keywordseo="mankind" source="Orion">Mankind</keyword> Pharma has announced its association with Vijay Sethupathi, an Indian actor and producer who predominantly has contributed in the Tamil cinema. In lieu of this association, Mankind Pharma, the company will be donating an amount of Rs 31 lakh to the Film Employees Federation of South India (FEFSI). FEFSI is an Indian organisation consisting of technicians from the <keyword id="6412552" type="General" weightage="20" keywordseo="tamil-film-industry" source="Orion">Tamil Film Industry</keyword> in Tamil Nadu, India. The amount donated will help all those who are facing a slowdown due to the pandemic and will support the growth of the organization and its members. Vijay Sethupathi has won 15 awards in the category of Best Actor which includes Filmfare Award- Tamil, <keyword id="128899" type="General" weightage="20" keywordseo="national-film-award" source="Orion">National Film Award</keyword>, <keyword id="12247905" type="General" weightage="20" keywordseo="vijay-award" source="Orion">Vijay Award</keyword> for Best actor and many more. Speaking on the partnership, Sethupathi said, “It is a pleasure to partner with Mankind Pharma as the brand ambassador and represent the brand in the southern market. The company perfectly justifies the true meaning of ‘Mankind’ and the motto of ‘Serving Life’ in the industry. I am honoured to be a part of the Mankind Pharma family and hope to serve the society together.” Speaking on the occasion, <keyword id="4921166" type="General" weightage="20" keywordseo="Rajeev-Juneja" source="Orion">Rajeev Juneja</keyword>, Managing Director and Vice Chairman, Mankind Pharma said, “We believe that Vijay Sethupathi is an ideal personality for us as a brand ambassador and has an emotional connect with the audience which is why people call him “People’s Treasure”. Both Mankind Pharma and the superstar have a common synergy and thought process of serving life in the country, and we feel this mutual alliance will be a prolific one for both of us. We at Mankind Pharma always selflessly contribute towards the betterment of the society and believe in serving life, we hope that the token amount donated to FEFSI will help provide assurance towards the growth of the company. Together we will continue to selflessly contribute towards the betterment of the society.” Mankind Pharma aspires to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs.

Mankind Pharma ropes in Vijay Sethupathi as its brand ambassador

<ul><li>Over 40 states in the US have filed a lawsuit against 20 drugmakers led by Teva Pharmaceuticals, an Israeli firm, for allegedly conspiring to raise prices of drugs. </li><li>Seven Indian drugmakers - <keyword id="44642" type="CITY" weightage="20" keywordseo="Sun-Pharma">Sun Pharma</keyword>, Dr Reddy’s Laboratories, Glenmark Pharma, Lupin Wockhardt, Zydus Pharma and Aurobindo Pharma - have been named in the antitrust lawsuit. </li><li>The lawsuit alleges that the concerned pharmaceutical firms colluded to raise the prices of over 100 medicines.</li></ul> Over 40 states in the US have <a href="https://www.livemint.com/industry/manufacturing/top-indian-drug-makers-accused-of-fixing-prices-1557774708125.html">filed a lawsuit</a> against 20 drugmakers led by Teva Pharmaceuticals, an Israeli firm, for allegedly conspiring to raise prices of drugs in the US market. Seven Indian drugmakers - Sun Pharma, Dr Reddy’s Laboratories, Glenmark Pharma, Lupin Wockhardt, Zydus Pharma and Aurobindo Pharma - have been named in the antitrust lawsuit, which was filed at the end of last week following the culmination of a multi-year investigation into the US pharma industry. Sun Pharma’s share price on the Bombay Stock Exchange <a href="https://www.google.com/search?q=sun+pharma+share+price&amp;rlz=1C1GCEU_enIN820IN820&amp;oq=sun+pharma+share+price&amp;aqs=chrome..69i57j0l5.4788j1j4&amp;sourceid=chrome&amp;ie=UTF-8">fell 13% </a>yesterday before recovering. The lawsuit alleges that the concerned pharmaceutical firms colluded to raise the prices of over 100 medicines and divide up the addressable market for the medicines as opposed to competing normally against each other. Teva is said to be <a href="https://www.philly.com/business/generics-teva-pennsylvania-new-jersey-drugs-price-fixing-20190513.html">the driving force </a>behind the collusion. Between 2013 and 2015, the Israel drugmaker reportedly fixed prices on 86 medicines, the complaint from the states alleged. The price increases on some drugs were as high as 1,000%. The drugmakers have to deal with more than just the lawsuit from the states. Even the US Department of Justice is investigating the companies for antitrust violations. Speaking on the matter, a spokesperson for Sun Pharma told <a href="https://www.livemint.com/industry/manufacturing/top-indian-drug-makers-accused-of-fixing-prices-1557774708125.html">Mint</a>, ““We believe the allegations made in these lawsuits are without merit and we will continue to vigorously defend against them." If successfully argued, the lawsuit could result in billions of dollars worth of fines for the concerned companies. The fines for Indian pharma firms are expected to be in <a href="https://timesofindia.indiatimes.com/business/india-business/7-indian-pharma-cos-face-lawsuits-from-over-40-us-states/articleshow/69315711.cms">the tens of millions of range</a>, since their participation was reportedly limited. For their part, the drugmakers have argued that the price increases were a result of market factors like supply shocks and consolidation among rivals. SEE ALSO: <a href="https://www.businessinsider.in/generic-drugs-are-americas-solution-to-high-branded-drug-prices-but-recent-events-suggest-the-markets-not-working/articleshow/67200320.cms">Generic drugs are America's solution to high branded drug prices. But recent events suggest the market's not working</a>

Seven Indian pharma companies are being dragged into a US lawsuit over high drug prices

India’s pharmaceutical industry is the third largest in the world, taking into consideration its volume and stands. But segment wise, it still lags behind its global counterparts. However, good news is, it’s maturing and people from various competitive sectors are joining the growing pharmaceutical industry. 
 
Indian drug makers are trying to get the vibes of international market after multinational peers in developed markets such as the US aren’t shying away from hiring the best senior-level talent. The scope of talent acquisition spills beyond the pharma industry. Once regarded as a less lucrative sector, pharmaceutical is a much sought after now. 
Now people from FMCG segment, which is a high paying one, are shifting to the ‘pharma’ field. 
 
 
Indian companies with scale and global aspirations tend to pay much higher than the domestic affiliates of multinational companies, offering as much as a 40% hike to hire talent at the chief executive level. Much of this differential is in the form of stock, providing wealth creation opportunities. 
 
If executives with experience in global markets have to be hired from multinational companies, the rate can jump by between 30-40% of their annual package, an industry executive told The Economic Times.

You Searched For "Indian pharma industry" and got 9 results

Indian pharma industry to log in 8-10% revenue growth this fiscal: Crisil

PTI

Indian pharma industry likely to grow at 10-13 pc in FY'21: Icra

PTI

Modi's 'self-reliance' call need of the hour: Pharma industry

PTI

Hiring in pharma sector will go up 20% in 2016. Here are the skills you will require

BI India Bureau

Boon or a bane: What does Trump’s latest proposal to import cheaper drugs mean for Indian pharma companies?

BI India Bureau

FOMO helps Gland Pharma swell on debut

Navdeep Yadav

Mankind Pharma ropes in Vijay Sethupathi as its brand ambassador

BI India Partner

Seven Indian pharma companies are being dragged into a US lawsuit over high drug prices

BI India Bureau

Is India’s pharmaceutical industry the next big thing in India?

BI India Bureau

Popular Keywords

Buying Guides